Belite Bio, Inc
BLTE
Classement en actions
#3051
Belite Bio, Inc. is a clinical-stage biopharmaceutical company focused on the... Belite Bio, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and advancement of novel therapies. The firm's primary therapeutic areas include atrophic age-related macular degeneration and autosomal recessive Stargardt disease. Its flagship drug candidate, LBS-008, is an investigational oral medication administered once daily. Currently undergoing Phase 3 clinical trials, LBS-008 is engineered to modulate vitamin A delivery to the eye, thus preventing the accumulation of detrimental vitamin A metabolites in ocular tissues. Furthermore, Belite Bio is advancing LBS-009, an oral anti-retinol binding protein 4 therapy, through preclinical development. This therapy targets various liver ailments, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes. Founded in 2016, Belite Bio, Inc. is headquartered in San Diego, California, and operates as a subsidiary of Lin Bioscience International Ltd.
Prix de l'action
$148.24
Dernière synchronisation: 2026-10-19
Capitalisation boursière
$5.97B
Changement (1 jour)
3.82%
Changement (1 an)
64.04%
Pays
US
Échange Belite Bio, Inc (BLTE)
Catégorie
Healthcare
Nombre d'actions en circulation pour Belite Bio, Inc (BLTE)
Nombre d'actions en circulation au June 2026: 40.18M
Selon les derniers rapports financiers et le cours de l'action de Belite Bio, Inc, le nombre actuel d'actions en circulation est de 40.18M. À la fin de December 2023, l'entreprise avait 26.59M actions en circulation. Le nombre d'actions en circulation est généralement affecté par les divisions d'actions et les rachats d'actions.
Historique des actions en circulation de Belite Bio, Inc (BLTE) de 2020 à 2026
Actions en circulation à la fin de chaque année
| Année | Actions en circulation | Changez |
|---|---|---|
| 2026 (TTM) | 40.18M | 31.58% |
| 2024 | 30.54M | 14.84% |
| 2023 | 26.59M | 33.12% |
| 2022 | 19.98M | -17.09% |
| 2021 | 24.10M | 161.73% |
| 2020 | 9.21M | 0.00% |
Actions en circulation pour des entreprises similaires ou concurrentes
| Entreprise | Actions en circulation | Différence | Pays |
|---|---|---|---|
| 253.90M | 531.87% |
US
|
|
| 396.00M | 885.51% |
US
|
|
| 478.91M | 1,091.85% |
AU
|
|
| - | - |
CH
|
|
| 62.19M | 54.76% |
NL
|
